DM2

A small pilot study reports experiences with use of a CBD/THC cocktail to mitigate symptoms in DM patients.

New prospective data provides insights into the incidence, circumstances, and consequences of falls in patients with DM1 and DM2.

The DM-Scope registry model supports the leveraging of clinical research to improve both therapeutic development and patient care.

MDF is pleased to announce the publication of the first-ever Consensus-based Care Recommendations for Congenital and Childhood-onset Myotonic Dystrophy Type 1 and Myotonic Dystrophy Type 2.

Defective insulin signaling activation may underlie skeletal muscle wasting in DM1 and DM2.

Myotonic designed this volunteer initiative to educate the next generation of medical professionals about myotonic dystrophy in order to improve clinical care and shorten the diagnostic odyssey. We need you!

Disorders of sleep and breathing are well characterized for DM1, but what about DM2?

A new review looks at the cross-disease evidence for RAN translation’s contributions to pathogenesis.

Publication of a new systematic review provides insights into clinical outcome measures for DM2.

Induced pluripotential stem cells (iPSCs) from DM2 provide new tools for CNS-focused mechanistic and translational studies.